Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient
Open Access
- 9 June 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (11), 2387-2391
- https://doi.org/10.1182/bloodadvances.2019000664
Abstract
Therapy with an IL-15 superagonist resulted in immune and clinical responses in a transplant recipient with PML.This publication has 36 references indexed in Scilit:
- Allogeneic BK Virus–Specific T Cells for Progressive Multifocal LeukoencephalopathyThe New England Journal of Medicine, 2018
- OMIP‐042: 21‐color flow cytometry to comprehensively immunophenotype major lymphocyte and myeloid subsets in human peripheral bloodCytometry Part A, 2017
- Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus controlJCI Insight, 2017
- Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS)Acta Neuropathologica, 2015
- In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infectionNeurology, 2013
- Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human BrainClinical Microbiology Reviews, 2012
- Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2Neurology, 2005
- Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathyAnnals of Hematology, 2002
- Association of Prolonged Survival in HLA-A2+ Progressive Multifocal Leukoencephalopathy Patients with a CTL Response Specific for a Commonly Recognized JC Virus EpitopeThe Journal of Immunology, 2002
- Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2Bone Marrow Transplantation, 1997